Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It
Royalties Will Fuel R&D Expansion
The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.
You may also be interested in...
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.